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Purpose: The purpose of  this study was to determine whether the wall thickening observed 
in vein grafts after they were placed into the arterial circulation could be inhibited by 
periadventitial delivery of  an insoluble sulfated polymer of  13-cyclodextrin (P-CDS) capable 
of  tightly binding heparin binding growth factors. 
Methods: Thirty-four New Zealand white rabbits underwent implantation of  reversed 
autologous jugular vein interposition grafts in the common carotid artery and were 
randomized to receive either 20 mg P-CDS (n = 18) topically around the graft or no 
additional therapy (n = 16). Before being killed at 28 days, animals were given 
bromodeoxyuridine to assess smooth muscle cell proliferation. Histomorphometric 
analyses were performed after perfusion fixation. 
Results: Compared to controls, treatment with P-CDS was associated with reduced mean 
intimal thickness (24+ 3 vs 38 +4 ~tm; mean+ SEM, p < 0.01) and intimal area 
(0.25 + 0.03 vs 0.54 + 0.09 ram2; p < 0.01). There was also significantly less medial 
thickness in the P-CDS group (45 + 3 vs 63 + 3, p < 0.001). There was no significant 
difference in intimal or medial smooth muscle cell proliferation between P-CDS-treated 
and control vein grafts at 28 days. The polymer persisted in the adventitia with a mild 
foreign body reaction. 
Conclusion: Periadventitial p acement ofP-CDS, a novel, insoluble, sulfated carbohydrate 
polymer, inhibits intimal and medial thickening of  vein bypass grafts in this model of  vein 
grafting. The persistence of  P-CDS in vivo for prolonged periods, and the ease of  topical 
application of  P-CDS during vascular bypasses may have important implications for its 
future use in vascular surgery. (J VASC SURG 1996;23:650-6.) 
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Vein grafts inserted into the arterial circulation 
develop intimal and medial thickening soon after 
implantation. Although wall thickening may be an 
appropriate healing response of  the vein to new 
conditions and forces in the arterial environment, it 
may also result in pathologic luminal narrowing, 
ultimately resulting in vein graft failure. Vein graft wall 
thickening is considered to be a leading cause o f  late 
vein graft f)ilure. 1,2 Recent studies demonstrate the 
pivotal role of  growth factors in the formation of  
intimal thickening after arterial injury3; growth fac- 
tors may also play an important role in the normal 
physiologic ondition and repair mechanisms of  the 
vessel wall. 4-6 The healing process ofauto logous vein 
grafts placed into the arterial circulation is likely to be, 
at least in part, in response to growth factor-mediated 
stimulation. Therefore agents that interact or inter- 
fere with growth factor activity may be beneficial for 
controll ing the wall thickening observed' after vein 
grafts are placed in the arterial circulation. 
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Heparin has been shown to inhibit proliferation 
and migration in vitro and inhibits intimal thickening 
in models of arterial injury, 7,8 although systemic 
continuous administration at higher levels is usually 
required. 9 However, heparin's action on smooth 
muscle cell (SMC) growth appears to be independent 
of its anticoagulant function. ~~ To avoid problems 
with systemic administration, local administration to 
the periadvcntitial space has also been successfully 
used to inhibit intimal thickening after arterial in- 
jury 11 but often requires implantation of a delivery 
vehicle. To provide periadventitial therapy without an 
additional delivery vehicle, we developed an in- 
soluble, sulfated carbohydrate polymer of ~-cyclo- 
dextrin (P-CDS) that has several properties that make 
it an attractive candidate o prevent intimal thickening 
associated with vein graft arterialization: (1) it has no 
anticoagulant properties, (2) it is stable for prolonged 
periods when implanted periadventitially in animals 
without oxicity, (3) it has the capacity to tightly bind 
heparin-binding growth factors (HBGF), and (4) it 
inhibits SMC proliferation and migration in vitro. ~2 
The purpose of this study was to determine whether 
periadventitial therapy with P-CDS would inhibit vein 
graft wall thickening after arterialization i a well- 
characterized rabbit model. 
METHODS 
Rabbit vein graft model. Thirty-four male New 
Zealand white rabbits (Hazelton Research, Denver, 
Pa.) weighing 3.0 to 3.5 kg at the time of the 
operation were anesthetized byintramuscular injec- 
tion with a solution composed of ketamine (50 
mg/kg) and xylazine (7 mg/kg). Surgery was per- 
formed under sterile conditions. A ventral midline 
incision was made in the neck, and the left jugular vein 
and common carotid artery were carefully exposed 
and dissected free from surrounding tissues. Heparin 
(1000 U; Sigma Chemical Co., St. Louis, Mo.) was 
given intravenously. The flow through the artery was 
interrupted with microvascular clips, and then a 15 
mm segment of the external jugular vein was excised, 
reversed, and interposed into the divided artery. 
Proximal and distal anastomoses were performed in 
an end-to-end fashion with interrupted 7-0 polypro- 
pylene sutures (Ethicon, Inc., Somerville, N.Y.). After 
graft implantation the experimental group received 
P-CDS as described below. The skin was closed with 
2-0 polyglactin suture. (Ethicon, Inc.). 
Treatment groups. Rabbits were randomized to 
treatment with P-CDS (n -- 18) or to a control group 
(n = 16) that underwent similar graft implantation 
and manipulation without polymer placement. 
P-CDS was provided as a dry, white powder by 
American Maize, Inc. (Hammonton, Ind.). With the 
vein graft in place, P-CDS was sprinkled topically to 
coat the graft. After placement of the dry polymer, 
three drops of normal saline solution were added to 
the treated area, making agel-like substance toassure 
that the entire circumference of the vein graft and 
proximal and distal anastomoses had adequate con- 
tact with the polymer. The P-CDS and saline solution 
mixture has a consistency much like wet sugar, and, 
because it has no significant architectural strength, it
did not prevent distention of the vein graft. All animal 
care was in compliance with the "Principles of Labo- 
ratory Animal Care" and the Guide for the Care and 
Use of Laboratory Animals (NIH Publication No.80- 
23, revised 1985). 
Harvesting procedure. Four weeks after vein 
graft implantation, at17, 9, and 1 hour before being 
killed, the animals received three doses (1 ml/kg) of 
5-bromo-2"deoxyuridine (BrdU, 30 mg/ml; Boeh- 
ringer Mannheim, Indianapolis, Ind.). The rabbits 
were anesthetized and intravenously injected with 
Evans blue dye (25 mg/kg) and hcparin (1000 U, 
Sigma Chemical Co.). Laparotomy was performed for 
placement of an abdominal ortic perfusion catheter 
and an inferior vcna cava drainage catheter. The 
animals were killed, and the vascular system was 
perfused with lactated Ringer's olution via a retro- 
grade cannula in the thoracic aorta. Perfusion fixation 
was performed with 10% formalin in neutral 0.1 
mol/L phosphate buffer at a pressure of 100 mm Hg 
in the standard fhshion, with the vein graft undis- 
turbed in situ. After perfusion fixation, with the head, 
neck, and upper thorax fixed, the left common carotid 
artery with the vein graft, and segments of the right 
carotid artery and the right jugular vein were removed 
and immersion fixed fbr an additional 48 hours. 
Structure. Samples of the midsection of the vein 
graft were used for histologic, morphometric, and 
immunohistochemical an lyses. Specimens were em- 
bedded in paraffin, cut in 4 gm sections and stained 
with hematoxylin and eosin, Verhoeff van Gicson 
(WG) stain, or Richardson's stain. Morphometric 
measurements were obtained with computer-based 
representation measuring (Biometrics, Nashville, 
Ind.). The inner intimal boundary was the luminal 
surface, and the intima-media boundary was identi- 
fied by the color gradient with the VVG stain and the 
Richardson stains, and also by the elastic fiber staining 
on VVG stain. The outer medial border was defined 
by the perivascular capillaries. The thickness of the 
vein wall compartments were determined at eight 
separate, qually spaced sites along the circumference 
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Fig. 1. Inhibition of rabbit jugular vein graft thickening by P-CDS. Tissue 
sections of vein grafts 28 days after implantation from control (A) and 
P-CDS-treated rabbits (B) were stained with Richardson's stain (trichrome). 
Sections are aligned along internal elastic laminae (white arrows) with lumen 
above and adventitia below. Periadventitial P-CDS particles (P) can be seen 
in adventitia with some tissue organization around them. Original magnifi- 
cation • 
of the vein. These values were averaged. The vein graft 
wall circumference was measured, and the cross- 
sectional vein wall compartment areas were identified 
as the product of the perimeter and the corresponding 
compartment thickness. Alternatively, sections were 
used for immunohistochemistry o detect BrdU- 
positive cells as previously described.IS These sections 
were counterstained with hematoxylin and eosin. The 
number of BrdU-positive cells and the total number 
of cells per unit area in both the media and the intima 
of control and P-CDS-treated vein grafts were 
counted manually. An optical graticule was used, and 
nuclei were counted per unit area at eight even 
intervals around the circumference. The intimal and 
medial boundaries were determined comparing cor- 
responding VVG-stained sections. The BrdU intimal 
and medial labeling indexes were defined as the 
number of BrdU-labeled cells divided by the total 
number of cells in that compartment. 
Statistical analysis. All data are expressed as 
mean + standard error of  the mean. A two-tailed, 
unpaired Student test was used to determine statis- 
tical significance. A p value greater than 0.05 was 
regarded as statistically significant. 
RESULTS 
There were two perioperative and two late deaths 
in both the P-CDS and the control groups. At harvest 
four vein grafts in the P-CDS group and five vein 
grafts in the control group were occluded. Therefore 
10 patent P-CDS-treated vein grafts and seven patent 
control grafts were available for further analysis and 
form the basis for all further analyses. 
Periadventitial, topical application of the carbohy- 
drate polymer, P-CDS, resulted in a significant reduc- 
tion in intimal and medial thickness compared with 
controls (Fig. 1). P-CDS treatment reduced intimal 
thickening by 38% (24 + 3 vs 38 + 4 ~tm, p < 0.01) 
and medial thickening by 28% (45 + 3 vs 63 + 3 ~tm, 
p<0.001)  (Fig. 2). There was also a significant 
inhibition of intimal area accumulation in the P- 
CDS-treated grafts compared with controls (54% 
reduction) (Fig. 3), whereas there was no significant 
reduction in medial area. 
The distribution of  intimal thickening present in 
the vein grafts was somewhat variable. The P-CDS 
vein grafts showed more uniformity of  intimal thick- 
ening. Four P-CDS grafts exhibited a striking reduc- 
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Fig. 2. P-CDS delivered locally inhibits vein graftintimal 
and medial thickening. Bar gr ph indicates mean thickness 
of intima and media of rabbit jugular vein interposition 
grafts, harvested at 28 days after implantation for control 
(shaded bars) and P-CDS-treated animals (black bars). 
Values represent mean + SEM. Asterisk represents p < 0.01 ; 














Fig. 3. P-CDS delivered locally inhibits intimal cross- 
sectional area accumulation. Bar graphindicates cross- 
sectional area of intima and media of rabbit jugular vein 
interposition grafts, harvested at 28 days after implantation 
fbr control (shaded bars) and PCDS-treated animals (black 
bars). Values represent mean + SEM. Asterisk represents 
p < 0.01. 
tion in intimal thickening, and fivc had modcrate to 
low intimal thickening. However, one of the P-CDS 
grafts displayed severe intimal thickening. In both 
groups thc SMCs in thc intima appeared to bc 
arranged in an irregular pattern with extracellular 
matrix between the cells. The media of control and 
P-CDS-treated vein grafts underwent concentric 
thickening and was less cellular in nature than the 
intima. VVG staining demonstrated elastin in the 
intima of control and P-CDS grafts, with a pre- 
dominance of collagen but not elastin staining in the 
media. 
The light microscopic appearance of the cells and 
the extracellular matrix in P-CDS and control grafts 
showed some variability and no consistent qualitative 
differences at 28 days. Thcrc was no histologic 
evidence of toxic effects of P-CDS in terms of 
endothelial cell and SMC structure or extracellular 
matrix appearance, and multinuclcatcd giant cells 
were seen around the P-CDS particles, suggestive of 
a mild foreign body reaction. Evans blue staining 
revealed 100% confluent endothelial lining in all 
patent vein grafts. 
Finally, wc assessed the dcgrcc ofSMC prolifera- 
tion at the time the animals were killed (28 days). At 
this time point, the overall degree of proliferation 
(-5%) was clearly higher than normal control jugular 
veins (<1%). However, there was no significant differ- 
cncc in the percentage ofintimal or medial SMC that 
were proliferating between the P-CDS-treated and 
control vein grafts (Table I). 
D ISCUSSION 
In this study we have demonstrated that pcriad- 
vcntitial delivery of polymeric 13cyclodextrin sulfate 
significantly reduces the development of  wall thick- 
ening in experimental vein bypass grafts at 28 days. 
This is thc first report of the use of a locally applied 
polymer, which is itself both therapeutic and nontoxic 
to reduce experimental vein graft wall thickening. 
Wall thickening develops in all vein grafts within a 
short period after implantation i to the arterial circu- 
lation. Vein graft wall thickening has been associated 
with vein graft stenoscs and is a leading cause of  late 
vein graft failure) Human autologous vein bypass 
graft studies 1'2 and experimental vein graft models ]43s 
have shown that the healing process consists of 
vascular SMC undergoing an early proliferative phase 
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Table I. Cell proliferation indexes of the media and intima of vein grafts at 28 days 
Control P-CDS p 
Media 0.04 _+ 0.008 0.05 _+ 0.01 NS 
Intima 0.06 + 0.0! 0.04 _+ 0.006 NS 
To determine the indexes, the number of cells staining positive in a segment of vein with an antibody to BrdU was divided by the total number 
of cells in the compartments listed. 
followed by a synthetic phase resulting in a rapid 
intimal thickening. SMC proliferation and migration 
are considered as the major processes inthe formation 
of vein graft intimal thickening. It is postulated that 
the healing process after vein graft implantation is 
driven by growth factors derived from vein graft 
SMCs and endothelial cells. 3,5,6 This hypothesis is 
strengthened by the observation that in rabbit vein 
grafts, SMC and endothelial cells continue to prolif- 
erate in the absence of detectable endothelial denu- 
dation or platelet accumulation. 14 
It has been suggested that HBGFs play a pivotal 
role in vessel remodeling after vascular injury. ~6 It is 
known that heparin and related glycosaminoglycans 
bind avidly to HBGF and may affect heir function. 17 
Heparin, P-CDS, and other heparin-like compounds, 
such as 13-cyclodextrin tetradecasulfate, inhibit SMC 
proliferation and migration in vitro and inhibit intimal 
thickening in animal models of arterial injury. 7'~~ 
Systemic administration of heparin, however, has 
yielded conflicting results with respect to its effects on 
wall thickening in experimental vein grafts. Makhoul 
et a1.16 reported that continuous intravenous admin- 
stration ofheparin significantly reduced intimal thick- 
ening in the rabbit carotid vein graft. Kohler ct al., 2~ 
using the same model of vein grafting, reported that 
heparin failed to reduce vein graft intimal thickening 
or SMC proliferation. Conflicting data on the effect of 
systemic administration of heparin on vein graft wall 
thickening have also been reported in studies with rat 
vein graft models. 21'z2 It is postulated that the mecha- 
nisms of intimal thickening in arterial injury models 
and vein graft models may differ. Structural and 
functional differences between veins and arteries 1'2~ 
may also explain why certain therapeutic regimens 
succeeded in reducing wall thickening in models of 
arterial injury but failed to reduce wall thickening in 
models of vein grafting. Therefore the results of 
successful reduction of wall thickening in arterial 
injury models can not directly be extrapolated to 
models of vein grafting. 
Multiple agents have been studied for their effects 
on vein graft remodeling with variable success. 23 26 
Mechanistically, blockade of growth factor function is 
an attractive option. Systemic administration of 
growth factor antagonists such as heparin may be 
harmful because growth factors are widespread and 
not limited to the vasculature. Wound healing in 
general could be impaired, resulting in a problem after 
surgical procedures. Furthermore, the usefulness of 
heparin is limited by its potential bleeding complica- 
tions and its higher dose requirements for inhibiting 
SMC proliferation and migration than the dose re- 
quired for anticoagulation. This stimulated the search 
for novel heparin mimics with the antiproliferative 
and antimigratory characteristics of heparin but that 
could be applied locally. Local applications of a 
pharmacologic compound may reduce its systemic 
effects and allow high concentrations and increascd 
efficiency at the target site. Monomeric I]-cyclodex- 
trin tetradecasulfate is a universal heparin analog, 
paralleling and exceeding the demonstrated cell 
modulating capabilities ofheparin without significant 
anticoagulant activities. ~9'27'28 We have previously 
shown that oral administration of this compound 
inhibits restenosis and intimal hyperplasia n a hyper- 
cholestcrolemic rabbit angioplasty model. ~s The 
polymer fbrm P-CDS has biologic and therapeutic 
activity in that it inhibits SMC proliferation and 
migration in vitro and inhibits the arterial wall re- 
sponse to injury. ~2 
In this study, the polymer was applied to the 
adventitial side of the vein graft and both anastomoses 
in the form of dry, fine powder. Hydration of the 
polymer yields a soft gel that has no architectural 
strength and does not interfere with vessel dilation. 
After hydration the polymer offers an internal hep- 
arin-like surface capable of absorbing HBGF proteins 
such as basic fibroblast growth factor (bFGF), 29 
platelet-derived growth factors, 3~ or vascular endo- 
thelial growth factor. 3~ Although the mechanism 
through which P-CDS reduces arterial and vein graft 
wall thickening is still unknown, we speculate that 
P-CDS may provide a sustained therapeutic effect by 
tightly binding and sequestering growth factors in the 
periadventitial space and that the cyclic structure of 
the carbohydrate polymer subunits render it relatively 
resistant to degradation. Previous tudies have dem- 
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onstrated the ability o f  P -CDS to t ightly b ind 
bFGF ~2'29 and prevent  prol i ferat ion o f  rat SMC in 
vitro by bFGF,  platelet-derived growth  fhctor-BB, 
and epidermal  growth factor. ~2 Whether  growth fac- 
tors generated in the wound site are sequestered and 
prevented f rom ga in ing access to their  cognate recep- 
tors remains to be investigated. However ,  wound 
heal ing in general  was not  impaired by the presence o f  
the po lymer in this model .  
At 28 days after injury, there was no  signif icant 
difference in medial  and int imal prol i ferat ion indexes 
between contro l  and P -CDS- t reated  vein grafts. This 
is concordant  with a study by Schwartz et al., ~s who 
reported that SMC prol i ferat ion in this model  o f  vein 
graft ing appears to begin  wi th in  24 hours  and to peak 
at 2 days but  then returns to normal  at 14 days. ~'~ 
Future  studies are needed to determine  whether  
P -CDS limits the early SMC proliferative burst  soon 
after implantat ion into the arterial c irculat ion, which 
may in part account  for the reduct ion  in int imal  
thickening.  
In summary,  this is the first report  o f  the successful 
use of  a locally applied novel heparin- l ike po lymer 
w i thout  an addit ional  delivery vehicle to reduce 
experimental  vein graft wall th ickening.  The ease of  
local appl ication o f  this po lymer at the t ime of  vascular 
surgery, especially at the site o f  anastomoses where 
int imal  th ickening is a particular prob lem,  will facili- 
tate its appl ication in human vascular bypasses. Fur- 
ther invest igat ions into  its mechan ism of  act ion seem 
warranted to opt imizc its uti l ity as a therapeut ic  agent. 
Microsutures were a gift of Ethicon Inc., Somerville, 
N.J. 
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